Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $226.26, with a market capitalization of 33.43B. The stock trades at a price-to-earnings (P/E) ratio of 40.30.
During the trading session on 2026-09-24, Biogen(BIIB) shares reached a daily high of $228.72 and a low of $224.31. At a current price of $226.26, the stock is +0.9% higher than the low and still -1.1% under the high.
Trading volume for Biogen(BIIB) stock has reached 297.76K, versus its average volume of 1.1M.
The stock's 52-week range extends from a low of $135.39 to a high of $229.19.
The stock's 52-week range extends from a low of $135.39 to a high of $229.19.
BIIB News
...
Biogen and Eisai recently reported multiple product updates, including Japan and China approvals for at-home subcutaneous LEQEMBI and fresh adolescent EMPAVELI...
Biogen (BIIB) announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating Empaveli in the Clin...
Analyst ratings
65%
of 37 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.